Celgene Corporation (NASDAQ: CELG) reported a 56% jump in earnings for the third quarter of 2019 helped by higher revenue as well as lower costs and expenses. The results exceeded analysts’ expectations.
Net income soared by 56% to $1.69 billion or $2.32 per share. Adjusted earnings climbed by 31% to $2.99 per share. Total revenue increased 16% to $4.52 billion. The results were benefited by increases in treatment duration and market share for multiple myeloma.
Looking ahead into the full year 2019, the company still expects adjusted earnings in the range of $10.65 to $10.85 per share. However, Celgene lowered its earnings forecast to the range of $8.39 to $9.10 per share from the previous range of $8.71 to $9.44 per share.
For the third quarter, Revlimid sales increased 13% driven primarily by the adoption of triplet therapy for myeloma resulting in increases in treatment duration and market share. Pomalyst/Imnovid sales jumped 29% on the adoption of triplet therapy for myeloma resulting in increases in treatment duration and market share.
Otezla sales climbed 27% on the increase in US demand and continued uptake in key international markets. Abraxane sales increased by 10% on increased demand due to immuno-oncology combinations in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
The pending merger between Bristol-Myers Squibb (NYSE: BMY) and Celgene is expected to close by the end of 2019. Due to the pending transaction, Celgene is not hosting a conference call in conjunction with its Q3 2019 earnings release and does not expect to do so for future quarters.
Most Popular
Walgreens Boots Alliance set to report Q2 earnings. Here’s what to expect
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), a market leader in health and wellness services, is preparing to report second-quarter results, with market watchers forecasting a mixed outcome. As part of
Chewy (CHWY) is set for meaningful growth in the coming year, here’s why
Shares of Chewy, Inc. (NYSE: CHWY) stayed red on Thursday. The stock has dropped 2% over the past three months. The pet products company ended fiscal year 2024 on a
GME Earnings: GameStop Q4 2024 profit rises; sales down 28%
Video game company GameStop Corp. (NYSE: GME) has reported an increase in fourth-quarter 2024 earnings, despite a double-digit fall in revenues. Net sales decreased to $1.28 billion in the fourth
